To scroll text in this page
Global Navigation end
News Release 2009
Astellas to Terminate the Development of Anti-Human Osteopontin Antibody ASK8007for RA
October 26, 2009
Japan, October 26, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that it has decided to terminate the development of ASK8007 (development code), anti-human osteopontin antibody for rheumatoid arthritis (RA). It was co-developed with Chemo-Sero-Therapeutic Research Institute (“KAKETSUKEN”; headquarters: Kumamoto, Kumamoto Prefecture).
Astellas and Immuno-Biological Laboratories Co., Ltd. (headquarters: Takasaki, Gunma Prefecture) concluded a worldwide licensing agreement which granted Astellas the exclusive rights to develop, manufacture, and market anti-human osteopontin antibodies, for therapeutic use in March 2006.
Astellas and KAKETSUKEN carried out Phase I for ASK8007 for RA; however, have concluded terminating the development for the field of RA by evaluating the result of the study comprehensively. Astellas is now considering a possible application of it to other indications than RA.
####
Printer-friendly version
Main Text end
- Message
- Business Philosophy
- VISION 2015
- CSR-Based Management
- Governance & Internal Control
- Business Activities
- Corporate Profile
- Disclosure Policy
- News Release
To view and print the files, you must have Adobe Reader.
Local Navigation end
